

– To create Wealth
Invest in Health



Introducing

Motilal Oswal S&P BSE Healthcare ETF

(An open ended fund replicating / tracking the S&P BSE Healthcare Total Return Index)

**THINK EQUITY
THINK MOTILAL OSWAL**


NFO

Opens: 14th July, 2022
Closes: 22nd July, 2022

INDEX FUNDS
by
MOTILAL OSWAL

— The Covid-19 Catastrophe

Pandemic made us realize importance of health system



'There are decades where nothing happens, and there are weeks where decades happen'


**–Vladmir Lenin
(Former premier)**

Source/ Disclaimer: The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

— Healthcare Sector by the numbers

Domestic healthcare sector on a strong footing

Rising income, increasing awareness, lifestyle diseases and increased access to insurance, suggests that healthcare sector will note robust growth




Source: NITI Ayog, Frost & Sullivan, LSI Financial Services, Deloitte. Bookmyforex for historical USD/INR values & 28/03/2022 value of USD/INR for 2022 F data. Data as per latest available report as of 30 March 2021. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

For Financial Professionals. Proprietary Content. Permission to reprint or distribute any content from this presentation requires the written approval of Motilal Oswal Asset Management Company.

Sector will be aided by increased government spending

The domestic healthcare sector will get shot in the arm as the Government plans to amp up spending and provide healthcare facilities to the economically weaker section



Source/ Disclaimer: indiabudget.gov.in. The above graph is used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy.

India-The pharmacy of the world

Domestic pharma market is pegged at **\$42 Billion** in 2021 and is expected to reach **\$130 Billion** by 2030




Accounts for
50%
of global vaccine
supplies

3rd Largest
market by volume



14th Largest
market by value

Largest
provider of generic
drugs globally




Source/ Disclaimer: IBEF. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.


Inadequate healthcare infrastructure indicates tremendous growth opportunity

India's doctor-population ratio and bed density ratio vis-à-vis other economies is relatively lower indicating strong growth potential

**Doctors
(per 10,000 population) [1]**



Hospital Bed density (per 10,000 population) [2]




Source: [1] WHO World Health Statistics 2020, [2] India bed density is estimated by CRISIL Research, tracking Universal health Coverage- 2017 Global Monitoring Report, World Bank Data base, CRISIL Research. The above graph is used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy.

Tailwinds for Diagnostics

- Domestic diagnostic industry estimated at ~\$9 Billion (2020) and is expected to grow at over 10% over next 5 years
- The diagnostics business is asset light model as it operates on hub and spoke model
- Only 20% of total diagnostic services are reimbursed via insurance claims, rest is out of pocket expense
- Inclusion of diagnostic tests under insurance coverage may lead to inflection in growth rate of the industry

India's out of pocket spending is at elevated levels (%)



Source: WHO, Kotak Institutional Equities


Source: Edelweiss Professional Investor Research 2020, Kotak Institutional Equity. The above graph is used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy.

India poised to be an attractive destination for Medical Tourism

- Medical tourism business pegged at \$5 billion in 2020
- Expected to become a \$14 billion business by 2023
- Medical tourism expected to grow at ~21% CAGR between 2020-27

Treatment costs in India well below global costs
Medical tourism Treatment cost (US\$)


Treatment	US	UK	Thailand	Singapore	India
Heart Surgery	100,000	40,000	14,000	15,000	5,000
Bone Marrow Transplant	250,000	290,000	62,000	150,000	30,000
Liver Transplant	300,000	200,000	75,000	140,000	45,000
Knee Replacement	48,000	50,000	8,000	25,000	6,000



India ranked #10th out of the top 46 countries for medical tourism

Source/Disclaimer: Average cost of treatment;- Kotak Institutional Equities, Market size- Trade promotion council of India & Kotak Institutional Equities. #medical tourism Index 2020-2021. The graphic is used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy.

Key Growth Drivers



Source/Disclaimer: *100% FDI permitted under automatic route in the hospital sector. In the pharmaceutical sector, 100% FDI in green field projects and 74% in brownfield projects. The graphic is used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy.

— About Motilal Oswal S&P BSE Healthcare ETF

Motilal Oswal S&P BSE Healthcare ETF



Type of Scheme

An open ended fund replicating/tracking S&P BSE Healthcare Total Return Index



Minimum Application Amount

On Exchange – Investors can buy/sell units of the Scheme in round lot of 1 unit and in multiples thereafter

Directly with Mutual Fund – Buy/sell units of the Scheme where the subscription / redemption amount is in excess of INR 25 Crs. However, the same limit is not applicable to Market makers.



Investment Objective

The investment objective of the scheme is to provide returns that, before expenses, correspond to the total returns of the securities as represented by S&P BSE Healthcare TRI, subject to tracking error. However, there is no guarantee or assurance that the investment objective of the scheme will be achieved



Exit Load

Nil



Date of Allotment

29-Jul-2022



Fund Manager

Mr. Swapnil Mayekar &
Mr. Abhiroop Mukherjee (debt component)



NFO Period

14-Jul-2022 to 22-Jul-2022





Indicative Total Expense Ratio

Regular- 0.20%

Source: MOAMC; As of 30-June-22. Mutual Fund Investments are subject to market risks, read all scheme related documents carefully

Product Suitability


Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p>Motilal Oswal S&P BSE Healthcare ETF (An open ended fund replicating / tracking the S&P BSE Healthcare Total Return Index)</p>	<ul style="list-style-type: none"> Return that corresponds to the total returns of the S&P BSE Healthcare Total Return Index subject to tracking error Long term capital growth 	<p style="text-align: center;">Fund</p> 	<p style="text-align: center;">S&P BSE Healthcare Total Return Index</p> 

*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.

About: S&P BSE Healthcare Total Return Index

Index Objective: The S&P BSE Healthcare Total Return Index is designed to provide investors exposure to companies included in the S&P BSE AllCap that are classified as members of the healthcare sector.

Index Methodology Snapshot:



Source: S&P BSE. Data as of Jun 30, 2022; for detailed index methodology kindly visit <https://www.spglobal.com/spdji/en/>.


S&P BSE Healthcare Index snapshot

Top 10 Constituents


S. No.	Constituent Name	Weight
1	Sun Pharmaceutical Industries Ltd	15.9%
2	Dr Reddy's Laboratories Ltd	9.5%
3	Cipla Ltd/India	8.3%
4	Divi's Laboratories Ltd	8.2%
5	Apollo Hospitals Enterprise Ltd	6.6%
6	Laurus Labs Ltd	3.2%
7	Max Healthcare Institute Ltd	3.0%
8	Lupin Ltd	2.6%
9	Aurobindo Pharma Ltd	2.6%
10	Torrent Pharmaceuticals Ltd	2.5%
--	Total	62.5%

Total number of constituents = 97

Basic Industry (AMFI) Coverage by Mcap (%)



SEBI Size Coverage by weight (%)



Source/Disclaimer: S&P BSE. Data as of 30-June-2022. Sectors – Basic Industry classification as per AMFI Industry Classification. The stocks/sectors mentioned above are used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy. The stock may or may not be part of our portfolio/strategy/ schemes. It should not be construed as investment advice to any party. Past performance may or may not be sustained in future.

— Sneak Peak into industries forming part of the index

Pharmaceutical


Includes manufacturing, extraction, processing, purification and packaging
Eg – Sun Pharma

Hospital

Includes healthcare centres, district hospital, general hospital & nursing homes. Eg – Apollo Hospital

Medical Equipment

Includes medical equipment and supplies. . Eg – Poly Medicure



Specialty Chemical

Includes manufacturing, extraction, processing, purification and packaging
Eg- Valient Organics


Diagnostic

Includes businesses and laboratories with analytical or diagnostic services.
Eg – Lal Path labs

Source/ Disclaimer: The stocks/sectors mentioned above are used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy. The stock may or may not be part of our portfolio/strategy/ schemes. It should not be construed as investment advice to any party

Historical Performance


S&P BSE Healthcare Total Return Index has significantly outperformed the broad market over the last 15 years



Source/Disclaimer: spglobal.com; Performance as of close of 30-June-07 to 30-June-22. Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

Calendar Year Performance

S&P BSE Healthcare Index has outperformed against S&P BSE All Cap Index in **8** out of last **14** calendar years



Source/Disclaimer: spglobal.com; Performance as of close of 31-Dec-07 to 30-June-22. Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

Outperformance to broader market

Data Label		1 year	3 year	5 year	10 year	15 year
S&P BSE Healthcare TRI	CAGR	-15.1%	19.7%	9.5%	12.8%	13.1%
S&P BSE AllCap TRI		0.8%	13.5%	11.4%	13.8%	10.6%
S&P BSE Healthcare TRI	Annualised Volatility	16.8%	20.4%	19.1%	17.8%	18.6%
S&P BSE AllCap TRI		17.4%	21.9%	18.7%	16.7%	21.3%
S&P BSE Healthcare TRI	Risk Adjusted Returns	-0.897	0.964	0.497	0.720	0.705
S&P BSE AllCap TRI		0.046	0.616	0.609	0.828	0.498

Source/Disclaimer: S&P BSE; Performance as of close of 30-June-07 to 30-June-22. Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

Index SIP returns

S&P BSE Healthcare TRI	1 Year	3 Year	5 Year	7 year	10 Year
Returns	-23.4%	12.0%	11.9%	8.7%	9.5%
Amount Invested	1,20,000	3,60,000	6,00,000	8,40,000	12,00,000
Market Value	1,04,332	4,30,297	8,07,645	11,45,290	19,60,539

Data as of close of June 30, 2022. For SIP returns, monthly investment of INR 10,000/- invested on the first business day of every month has been considered. Performance is calculated using Total Return Index, with zero cost/expenses. Past performance may or may not be sustained in the future

Source/Disclaimer: S&P BSE; Performance as of Close of 02-July-2012 to 30-June-2022; Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. The above table is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy. The SIP amount, tenure of SIP, expected rate of return are assumed figures for the purpose of explaining the concept of advantages of SIP investments. The actual result may vary from depicted results depending on scheme selected. It should not be construed to be indicative of scheme performance in any manner. The above are not scheme SIP returns, but simulation of index SIP returns. Past performance may or may not be sustained in future.


Better odds of double digit returns!

	3 Year Rolling Returns		5 Year Rolling Returns	
	S&P BSE Healthcare TRI	S&P BSE AllCap TRI	S&P BSE Healthcare TRI	S&P BSE AllCap TRI
Average	15.9%	11.8%	15.1%	12.1%
Median	18.1%	12.4%	14.7%	13.1%
Min	-9.8%	-5.9%	-6.4%	-1.8%
Max	43.2%	33.4%	33.8%	24.3%
Returns Range	% of Total Observation			
Negative	19.5%	5.2%	5.9%	1.1%
0% to 10%	6.2%	32.2%	23.3%	32.2%
10% to 15%	10.7%	29.5%	21.5%	28.6%
15% to 20%	74.2% }	62.2% }	71.4% }	65.8% }
Above 20%	40.6%	12.5%	33.5%	1.8%

Source/Disclaimer: S&P BSE. 250 trading days assumed in one year. Performance data since 16-Sep-05 to 30-June-22. All Performance data in INR. Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. The above table is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy. Past performance may or may not be sustained in future

Lower drawdowns over last 15 years

As healthcare sector is a defensive play, the S&P BSE Healthcare Index has historically seen smaller drawdowns vs its benchmark



Source/Disclaimer: S&P BSE; Performance as of close of 30-June-07 to 30-June-22. Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

Performance across market cycles

Market Cycle	Nifty 50 TRI	S&P BSE Healthcare TRI	S&P BSE AllCap TRI
Bull	23.4%	9.5%	24.6%
Bear	-38.5%	-17.3%	-41.6%
Recovery	39.6%	49.4%	45.3%


- Healthcare sector tends to be a defensive play
- The S&P BSE healthcare Index has historically outperformed the broader benchmarks during Bear and recovery market cycles

Source/Disclaimer: S&P BSE. 250 trading days assumed in one year. Performance data since 16-Sep-05 to 30-June-22. All Performance data in INR. Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. The above table is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy. Past performance may or may not be sustained in future

— Comparison peer indices

S&P BSE Healthcare Total Return Index provides broadest exposure


	S&P BSE Healthcare TRI	Nifty Healthcare TRI	Nifty Pharmaceutical TRI
No. of companies	Variable (Currently 97)	Fixed (20)	Fixed (20)
Industry coverage	All 7	2 out of 7	1 out of 7
Coverage of healthcare universe	~99%	~70%	~68%
Largest Industry	Pharmaceutical; 81%	Pharmaceutical; 87%	Pharmaceutical; 100%
Largest stock	Sun Pharmaceutical Ltd. 15.8%	Sun Pharmaceutical Ltd. 20.8%	Sun Pharmaceutical Ltd. 22.4%



Source: spglobal.com; niftyindices.com; Data as on 30-June-22 for BSE Healthcare TRI; S&P BSE Healthcare TRI Index launch date – 25th Feb 22; Nifty Healthcare TRI, 18th November 20; Nifty Pharma TRI, 1 July 2005. . The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

Performance over peer indices

S&P BSE Healthcare Index has outperformed Nifty Healthcare Index and Nifty Pharma Index



Source/Disclaimer: S&P BSE; Performance as of close of 30-June-07 to 30-June-22. Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

Performance over peers



Annualized Returns

Parameters	1 year	3 year	5 year	10 year	15 year
S&P BSE Healthcare TRI	-15.1%	19.7%	9.5%	12.8%	13.1%
Nifty Healthcare TRI	-14.0%	18.0%	7.8%	11.1%	11.8%
Nifty Pharma TRI	-14.4%	15.6%	5.6%	9.5%	11.2%
Nifty 50 TRI	1.7%	11.6%	12.0%	13.0%	10.3%

Source/Disclaimer: Index values- niftyindices; asiaindex; S&P BSE; Performance as of close of 30-June-07 to 30-June-22. Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above table is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

Why should you invest in Motilal Oswal S&P BSE Healthcare ETF?



One of the fastest growing sectors in India

Has strong tailwinds such as rising healthcare awareness among citizens.

Offers broadest exposure among peer indices.

Defensive play


Source/ Disclaimer: The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

29 For Financial Professionals. Proprietary Content. Permission to reprint or distribute any content from this presentation requires the written approval of Motilal Oswal Asset Management Company.



— Annexure

Historical Industry Breakup




Others = Healthcare service providers, Medical equipment & supplies, Healthcare research, healthcare analytics, healthcare technology etc

Source/Disclaimer: S&P BSE; Data from 31-Sep-13 to 30-Jun-2022. *. Basic Industry as per AMFI Industry Classification as on 30-June-22. The industries mentioned above are used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy. The sectors may or may not be part of our portfolio/strategy/schemes. It should not be construed as investment advice to any party.

Exposure to All Caps

S&P BSE Healthcare Index has healthy mix of Large Mid and Small Cap Stocks



Source/Disclaimer: S&P BSE; Data from 30-Sep-18 to 30-June-2022. Size classification as per AMFI; . The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

Performance vs Nifty 50

Data Label		1 year	3 year	5 year	10 year	15 year
S&P BSE Healthcare TRI	CAGR	-15.1%	19.7%	9.5%	12.8%	13.1%
Nifty 50 TRI		1.7%	11.6%	12.0%	13.0%	10.3%
S&P BSE Healthcare TRI	Annualised Volatility	16.8%	20.4%	19.1%	17.8%	18.6%
Nifty 50 TRI		17.1%	22.7%	19.2%	17.1%	22.1%
S&P BSE Healthcare TRI	Risk Adjusted Returns	-0.897	0.964	0.497	0.720	0.705
Nifty 50 TRI		0.097	0.510	0.628	0.758	0.467

Source/Disclaimer: S&P BSE; Performance as of close of 30-June-07 to 30-June-22. Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above table is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

Existing healthcare funds




Existing passive funds track the Nifty Healthcare Index

Passive Funds				Expense Ratio	
Sr.No	Scheme Name	Inception Date	AUM (in Rs Cr)	Regular	Direct
1	ICICI Pru Healthcare ETF	18-May-21	106	-	0.2
2	Aditya Birla SL Nifty Healthcare ETF	21-Oct-21	26.1	-	0.1
3	Axis Healthcare ETF	17-May-21	19.6	-	0.2

Active Funds				Expense Ratio	
Sr.No	Scheme Name	Inception Date	AUM (in Rs Cr)	Regular	Direct
1	ICICI Pru Pharma Healthcare & Diagnostics (P.H.D) Fund-(G)	13-Jul-18	2316.1	2.1	1.2
2	Mirae Asset Healthcare Fund-Reg(G)	02-Jul-18	1691.6	2.1	0.6
3	SBI Healthcare Opp Fund-Reg(IDCW)	03-Jul-99	1638.3	2.1	1.1
4	DSP Healthcare Fund-Reg(G)	30-Nov-18	1178.6	2.2	0.8
5	UTI Healthcare Fund-Reg(IDCW)	25-Aug-99	706.5	2.5	1.2
6	Tata India Pharma & Healthcare Fund-Reg(G)	28-Dec-15	508.2	2.4	1.0
7	Aditya Birla SL Pharma & Healthcare Fund-Reg(G)	10-Jul-19	470.3	2.6	1.0
8	ITI Pharma & Healthcare Fund-Reg(G)	08-Nov-21	158.9	2.5	0.3
9	Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund-Reg(G)	26-Oct-20	157.1	1.1	0.5
10	IDBI Healthcare Fund-Reg(G)	28-Feb-19	62.3	2.5	1.2


Indian healthcare still at a nascent stage

Per capita healthcare spending remains one of the lowest globally
March fiscal year-end, 2021 (USD)




Source: WHO, Kotak Institutional Equities

Spend on healthcare in the consumption mix set to increase (%)



Source: McKinsey, Kotak Institutional Equities

India healthcare market break-up by revenue
March fiscal year-end, 2021 (%)




India needs to add 1.5 mn additional beds over the next decade



Source/Disclaimer: Kotak Institutional Equities; Data as per latest available report as of June 202. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

eHealth- a new norm in post Covid era

On the back of rapid digitization and increased government support **India's eHealth market is estimated to touch \$10.6bn by 2025**



- eHealth includes teleconsulting, e-pharmacies, e-diagnostics and online fitness and wellness
- With dual benefit of lower price and more convenience we may see increased adoption of the services


Source/ Disclaimer: INC42- Decoding ehealth opportunity. Article published on Jan 2021. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

eHealth startups landscape




Source/Disclaimer: INC42. Companies shown above are used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy. The company may or may not be part of our portfolio/strategy/ schemes. It should not be construed as investment advice to any party.

Motilal Oswal Passive Fund Offerings



Motilal Oswal Passive Fund Offerings



Motilal Oswal Passive Fund Offerings



Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p>Motilal Oswal Nifty 50 Index Fund (An open ended scheme replicating / tracking Nifty 50 Index)</p>	<ul style="list-style-type: none"> Return that corresponds to the performance of Nifty 50 Index subject to tracking error Equity and Equity related securities covered by Nifty 50 Index Long-term capital growth 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>Nifty 50 TRI</p> <p>Investors understand that their principal will be at very high risk</p>
<p>Motilal Oswal Nifty Next 50 Index Fund (An open ended scheme replicating / tracking Nifty Next 50 Index)</p>	<ul style="list-style-type: none"> Return that corresponds to the performance of Nifty Next 50 Index subject to tracking error Equity and Equity related securities covered by Nifty Next 50 Index Long-term capital growth 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>Nifty Next 50 TRI</p> <p>Investors understand that their principal will be at very high risk</p>
<p>Motilal Oswal Nifty Midcap 150 Index Fund (An open ended scheme replicating / tracking Nifty Midcap 150 Index)</p>	<ul style="list-style-type: none"> Return that corresponds to the performance of Nifty Midcap 150 Index subject to tracking error Equity and Equity related securities covered by Nifty Midcap 150 Index Long-term capital growth 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>Nifty Midcap 150 TRI</p> <p>Investors understand that their principal will be at very high risk</p>
<p>Motilal Oswal Nifty Smallcap 250 Index Fund (An open ended scheme replicating / tracking Nifty Smallcap 250 Index)</p>	<ul style="list-style-type: none"> Return that corresponds to the performance of Nifty Smallcap 250 Index subject to tracking error Equity and Equity related securities covered by Nifty Smallcap 250 Index Long-term capital growth 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>Nifty Smallcap 250 TRI</p> <p>Investors understand that their principal will be at very high risk</p>

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p>Motilal Oswal Nifty 500 Index Fund (An open ended scheme replicating / tracking Nifty 500 Index)</p>	<ul style="list-style-type: none"> Return that corresponds to the performance of Nifty 500 Index subject to tracking error Equity and Equity related securities covered by Nifty 500 Index Long-term capital growth 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>Nifty 500 TRI</p> <p>Investors understand that their principal will be at very high risk</p>
<p>Motilal Oswal Nifty 50 ETF (An open ended scheme replicating/tracking Nifty 50 Index) (BSE: 590115, NSE: MOM50)</p>	<ul style="list-style-type: none"> Return that corresponds generally to the performance of Nifty 50 Index (Underlying Index), subject to tracking error Investment in equity securities of Nifty 50 Index 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>Nifty 50 TRI</p> <p>Investors understand that their principal will be at very high risk</p>
<p>Motilal Oswal Nifty Midcap 100 ETF (An open ended scheme replicating/tracking Nifty Midcap 100 Index) (BSE: 536960, NSE: MOM100)</p>	<ul style="list-style-type: none"> Return that corresponds generally to the performance of Nifty Midcap 100 Index subject to tracking error Investment in equity securities of Nifty Midcap 100 Index 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>Nifty Midcap 100 TRI</p> <p>Investors understand that their principal will be at very high risk</p>
<p>Motilal Oswal Nifty Bank Index Fund (An open ended scheme replicating / tracking Nifty Bank Index)</p>	<ul style="list-style-type: none"> Return that corresponds to the performance of Nifty Bank Index subject to tracking error Equity and Equity related securities covered by Nifty Bank Index Long-term capital growth 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>Nifty Bank TRI</p> <p>Investors understand that their principal will be at very high risk</p>

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p>Motilal Oswal S&P 500 Index Fund (An open ended scheme replicating / tracking S&P 500 Index)</p>	<ul style="list-style-type: none"> Return that corresponds to the performance of S&P 500 Index subject to tracking error Investment in equity securities of S&P 500 Index 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>S&P 500 TRI (INR)</p> <p>Investors understand that their principal will be at very high risk</p>
<p>Motilal Oswal NASDAQ 100 ETF (An open ended scheme replicating/tracking NASDAQ-100 Index) (BSE: 533385, NSE: MOFN100)</p>	<ul style="list-style-type: none"> Return that corresponds generally to the performance of NASDAQ 100 Index subject to tracking error Investment in equity securities of NASDAQ 100 Index 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>NASDAQ 100 TRI (INR)</p> <p>Investors understand that their principal will be at very high risk</p>
<p>Motilal Oswal NASDAQ 100 Fund of Fund (An open ended fund of fund scheme investing in Motilal Oswal Nasdaq 100 ETF)</p>	<ul style="list-style-type: none"> Long term capital appreciation Return that corresponds to the performance of Motilal Oswal NASDAQ 100 ETF (MON100) Scheme through investment in units of MON100 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>NASDAQ 100 TRI (INR)</p> <p>Investors understand that their principal will be at very high risk</p>

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p>Motilal Oswal Asset Allocation Passive Fund of Fund – Aggressive (An open ended fund of funds scheme investing in passive funds)</p>	<ul style="list-style-type: none"> To generate long term growth/capital appreciation by offering asset allocation Investment solution that predominantly invests in passive funds such as ETF/Index Funds of equity and equity related instruments (domestic as well as international), fixed income and Gold 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>50% Nifty 500 TRI + 20% S&P 500 TRI (INR) + 10% Domestic Price of Gold + 20% Nifty 5 Yr Benchmark G-Sec Index</p> <p>Investors understand that their principal will be at very high risk</p>
<p>Motilal Oswal Asset Allocation Passive Fund of Fund – Conservative (An open ended fund of funds scheme investing in passive funds)</p>	<ul style="list-style-type: none"> To generate long term growth/capital appreciation with relatively lower volatility by offering asset allocation Investment solution that predominantly invests in passive funds such as ETF/Index Funds of equity and equity related instruments (domestic as well as international), fixed income and Gold 	<p>Fund</p> <p>Investors understand that their principal will be at high risk</p>	<p>30% Nifty 500 TRI + 10% S&P 500 TRI (INR) + 10% Domestic Price of Gold + 50% Nifty 5 Yr Benchmark G-Sec Index</p> <p>Investors understand that their principal will be at high risk</p>
<p>Motilal Oswal Nifty 5 Year Benchmark G-sec ETF (An open ended scheme replicating/tracking Nifty 5 yr Benchmark G-Sec Index) (BSE: 543250, NSE: MOGSEC)</p>	<ul style="list-style-type: none"> Return that corresponds generally to the performance of Nifty 5 yr Benchmark G-sec Index subject to tracking error Investment in securities of Nifty 5 yr Benchmark G-sec Index 	<p>Fund</p> <p>Investors understand that their principal will be at moderate risk</p>	<p>Nifty 5 yr Benchmark G-Sec Index</p> <p>Investors understand that their principal will be at moderate risk</p>

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p>Motilal Oswal 5 Year G-sec FoF (An open ended fund of funds scheme investing in units of Motilal Oswal 5 Year G-Sec ETF)</p>	<ul style="list-style-type: none"> Long term capital appreciation Return that corresponds generally to the performance of the Scheme, Motilal Oswal 5 Year G-Sec ETF through investment in units of Motilal Oswal 5 Year G-Sec ETF 	<p>Fund</p> <p>Investors understand that their principal will be at moderate risk</p>	<p>Nifty 5 yr Benchmark G-Sec Index</p> <p>Investors understand that their principal will be at moderate risk</p>
<p>Motilal Oswal MSCI EAFE Top 100 Select Index Fund (An open ended scheme replicating/ tracking MSCI EAFE Top 100 Select Index)</p>	<ul style="list-style-type: none"> Returns that corresponds to the performance of MSCI EAFE Top 100 Select Index, subject to tracking error. Long term capital growth. 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>MSCI EAFE Top 100 Select Index (INR)</p> <p>Investors understand that their principal will be at very high risk</p>
<p>Motilal Oswal NASDAQ Q 50 ETF (An open ended scheme replicating/ tracking Nasdaq Q-50 Index) (BSE: 543437, NSE:MONQ50)</p>	<ul style="list-style-type: none"> Return that corresponds to the performance of the NASDAQ Q-50 TR Index subject to tracking error and forex movement. Long term capital growth. 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>NASDAQ Q-50 Total Return Index (INR)</p> <p>Investors understand that their principal will be at very high risk</p>



*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p>Motilal Oswal Nifty 200 Momentum 30 ETF (An open ended fund replicating / tracking the Nifty 200 Momentum 30 Total Return Index) (BSE: 543465, NSE: MOMOMENTUM)</p>	<ul style="list-style-type: none"> Return that corresponds to the total returns of the Nifty 200 Momentum 30 Total Return Index subject to tracking error Long term capital growth 	<p>Fund</p>	<p>Nifty 200 Momentum 30 TRI</p>
<p>Motilal Oswal Nifty 200 Momentum 30 Index Fund (An open ended fund replicating / tracking the Nifty 200 Momentum 30 Total Return Index)</p>	<ul style="list-style-type: none"> Return that corresponds to the total returns of the Nifty 200 Momentum 30 Total Return Index subject to tracking error Long term capital growth 	<p>Fund</p>	<p>Nifty 200 Momentum 30 TRI</p>
<p>Motilal Oswal S&P BSE Low Volatility ETF (An open ended fund replicating / tracking the S&P BSE Low Volatility Total Return Index) (BSE: 543501, NSE: MOLOWVOL)</p>	<ul style="list-style-type: none"> Return that corresponds to the total returns of the S&P BSE Low Volatility Total Return Index subject to tracking error Long term capital growth 	<p>Fund</p>	<p>S&P BSE Low Volatility Total Return Index</p>

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p>Motilal Oswal S&P BSE Low Volatility Index Fund (An open ended fund replicating / tracking the S&P BSE Low Volatility Total Return Index)</p>	<ul style="list-style-type: none"> Return that corresponds to the total returns of the S&P BSE Low Volatility Total Return Index subject to tracking error Long term capital growth 	<p style="text-align: center;">Fund</p>  <p style="text-align: center; font-size: small;">Investors understand that their principal will be at very high risk</p>	<p style="text-align: center;">S&P BSE Low Volatility Total Return Index</p>  <p style="text-align: center; font-size: small;">Investors understand that their principal will be at very high risk</p>

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

Thank You

“Don’t look for the needle in the haystack. Just buy the haystack!”

- **John C. Bogle**

Contact Us -

Speak: +91-22 40548002 | 8108622222

Write: mfservice@motilaloswal.com

Visit: www.motilaloswalmf.com

Disclaimers & Risk Factors



This presentation has been prepared and issued on the basis of internal data, publicly available information and other sources believed to be reliable. The information contained in this document is for general purposes only and not a complete disclosure of every material fact and terms and conditions. The information / data herein alone is not sufficient and shouldn't be used for the development or implementation of an investment strategy. It should not be construed as investment advice to any party.

All opinions, figures, charts/graphs, estimates and data included in this presentation are as on date and are subject to change without notice. The statements contained herein may include statements of future expectations and other forward-looking statements that are based on our current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Readers shall be fully responsible / liable for any decision taken on the basis of this presentation. Investments in Securities are subject to market and other risks and there is no assurance or guarantee that the objectives of any of the Schemes will be achieved. The scheme may not be suited to all categories of investors.

The material is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. Opinions, if any, expressed are our opinions as of the date of appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. Recipient shall understand that the aforementioned statements cannot disclose all the risks and characteristics. The recipient is requested to take into consideration all the risk factors including their financial condition, suitability to risk return, etc. and take professional advice before investing.

Passive Investments - The Scheme is not actively managed. Since the Scheme is linked to index, it may be affected by a general decline in the Indian markets relating to its underlying index. The Scheme as per its investment objective invests in Securities which are constituents of its underlying index regardless of their investment merit. The AMC does not attempt to individually select stocks or to take defensive positions in declining markets.

Index Fund - The Scheme being an index scheme follows a passive investment technique and shall only invest in Securities comprising one selected index as per investment objective of the Scheme. The Fund Manager would invest in the Securities comprising the underlying index irrespective of the market conditions. If the Securities market declines, the value of the investment held by the Scheme shall decrease.

Risks associated with overseas investment

To the extent the assets of the scheme are invested in overseas financial assets, there may be risks associated with currency movements, restrictions on repatriation and transaction procedures in overseas market. Further, the repatriation of capital to India may also be hampered by changes in regulations or political circumstances as well as the application to it of other restrictions on investment. In addition, country risks would include events such as introduction of extraordinary exchange controls, economic deterioration, and bi-lateral conflict leading to immobilisation of the overseas financial assets and the prevalent tax laws of the respective jurisdiction for execution of trades or otherwise.

Currency Risk:

The fund may invest in overseas mutual fund / foreign securities as permitted by the concerned regulatory authorities in India. Since the assets will be invested in securities denominated in foreign currencies, the Indian Rupee equivalent of the net assets, distributions and income may be adversely affected by changes/fluctuations in the value of the foreign currencies relative to the Indian Rupee.

Country Risk:

The Country risk arises from the inability of a country, to meet its financial obligations. It is the risk encompassing economic, social and political conditions in a foreign country, which might adversely affect foreign investors' financial interests.

Investors are requested to note that they will be bearing the recurring expenses of the fund of funds (FoF) scheme, in addition to the expenses of underlying schemes in which the fund of funds scheme makes investments.

Mutual Fund Investments are subject to market risks, read all scheme related documents carefully

Disclaimers & Risk Factors



NSE Indices Limited Disclaimer: Motilal Oswal Nifty 200 Momentum 30 ETF & Motilal Oswal Nifty 200 Momentum 30 Index Fund offered by Motilal Oswal Asset Management Company Limited (MOAMC) or its affiliates is not sponsored, endorsed, sold or promoted by NSE Indices Limited and its affiliates. NSE Indices Limited and its affiliates do not make any representation or warranty, express or implied (including warranties of merchantability or fitness for particular purpose or use) to the owners of the above-mentioned schemes or any member of the public regarding the advisability of investing in securities generally or in the above-mentioned schemes linked to Nifty 200 Momentum 30 Index or particularly in the ability of Nifty 200 Momentum 30 Index to track general stock market performance in India. Please read the full Disclaimers in relation to the Nifty 200 Momentum 30 Index in the Scheme Information Document.

BSE

The Bombay Stock Exchange Limited (“the Exchange”) has given vide its letter dated February 10, 2011 permission to the Mutual Fund to use the Exchange’s name in this Scheme Information Document as one of the stock exchanges on which the Mutual Fund’s units are proposed to be listed subject to, the Mutual Fund fulfilling the various criteria for listing. The Exchange has scrutinized this Scheme Information Document for its limited internal purpose of deciding on the matter of granting the aforesaid permission to the Mutual Fund. The Exchange does not in any manner:-

1. warrant, certify or endorse the correctness or completeness of any of the contents of this SID;
2. warrant that the Mutual Fund’s units will be listed or will continue to be listed on the Exchange;
3. take any responsibility for the financial or other soundness of the Mutual Fund, its sponsors, its promoters, its management or any scheme or project of this Mutual Fund.

and should not for any reason be deemed or construed that the Scheme Information Document has been cleared or approved by the Exchange. Every person who desires to apply for or otherwise acquire any units of any scheme of this Mutual Fund may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be suffered by such person consequent to or in connection with such subscription /acquisition whether by reason of anything stated or omitted to be stated herein or any other reason whatsoever. Mutual Fund Investments are subject to market risks, read all scheme related documents carefully